fulvoplumierin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5281541 |
| CHEMBL ID | 445545 |
| CHEBI ID | 5188 |
| SCHEMBL ID | 436269 |
| MeSH ID | M0068039 |
| Synonym |
|---|
| nsc-609064 |
| cyclopenta[c]pyran-4-carboxylic acid,7-dihydro-1-oxo-, methyl ester, (e,e)- |
| nsc-661970 |
| NSC609064 , |
| nsc661970 |
| plumiera rubra |
| (e,e)-7-(2-butenylidene)-1,7-dihydro-1-oxocyclopenta[c]pyran-4-carboxylic acid methyl ester |
| methyl (7e)-7-[(e)-but-2-enylidene]-1-oxo-cyclopenta[c]pyran-4-carboxylate |
| fulvoplumierin |
| 20867-01-0 |
| C09778 |
| chebi:5188 , |
| CHEMBL445545 |
| nsc 609064 |
| nsc 661970 |
| cyclopenta(c)pyran-4-carboxylic acid, 7-(2-butenylidene)-1,7-dihydro-1-oxo-, methyl ester, (e,e)- |
| 88w5o194bu , |
| unii-88w5o194bu |
| methyl 7-crotonylidenecyclopenta(c)pyran-1-(7h)-one-4-carboxylate |
| (7e)-7-(2e)-buten-1-ylidene-1,7-dihydro-1-oxocyclopenta(c)pyran-4-carboxylic acid methyl ester |
| methyl 7-crotonylidenecyclopenta(c)pyran-1(7h)-one-4-carboxylate |
| (e,e)-7-(2-butenylidene)-1,7-dihydro-1-oxocyclopenta(c)pyran-4-carboxylic acid methyl ester |
| cyclopenta(c)pyran-4-carboxylic acid, 7-(2e)-2-butenylidene-1,7-dihydro-1-oxo-, methyl ester, (7e)- |
| fulvoplumierin [mi] |
| 3-(2-butenylidene)-2-carboxy-.alpha.-(hydroxymethylene)-1,4-cyclopentadiene-1-acetic acid .delta.-lactone methyl ester |
| SCHEMBL436269 |
| bdbm50480323 |
| (e,e)-7-(2-butenylidene)-1,7-dihydro-1-oxo-cyclopenta(c)pyran-4-carboxylic acid methyl ester |
| Q27106683 |
| DTXSID101126054 |
| methyl (7e)-7-(2e)-2-buten-1-ylidene-1,7-dihydro-1-oxocyclopenta[c]pyran-4-carboxylate |
| Class | Description |
|---|---|
| carbonyl compound | Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. |
| pyrans | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID336525 | Cytotoxicity against human breast cancer cells | |||
| AID336528 | Cytotoxicity against human KB cells | |||
| AID336523 | Cytotoxicity against human HT1080 cells | |||
| AID1540637 | Inhibition of human DNA ligase 1 using 52-mer DNA/25-mer DNA/27-mer DNA as substrate by fluorescence assay | 2019 | European journal of medicinal chemistry, Nov-15, Volume: 182 | Recent advances in the targeting of human DNA ligase I as a potential new strategy for cancer treatment. |
| AID336527 | Cytotoxicity against human colon cancer cells | |||
| AID336524 | Cytotoxicity against human melanoma cells | |||
| AID397122 | Inhibition of HIV1 RT | |||
| AID336526 | Cytotoxicity against human lung cancer cells | |||
| AID336529 | Cytotoxicity against mouse P388 cells | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (20.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||